Accredited E-Newsletter Series
How I Approach MDS Diagnosis and Risk Assessment CME, CPE Hetty E. Carraway, MD, MBA, FACP | ||
Release Date: August 04, 2021 Expiration Date: August 04, 2022 | ||
Join Dr. Carraway as she outlines her strategy for diagnosing myelodysplastic syndromes (MDS) and assessing disease risk. In this newsletter, she reviews differential diagnoses for cytopenias/dysplasia, critical diagnostic tests to include in the MDS diagnostic pathway, MDS subtyping and classification, important prognostic factors and scoring systems, and the impact of somatic mutations on disease course and treatment selection. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc. | ||
View Only, No Credit | ||
Management of Hypomethylating Agent (HMA) Failure in Myelodysplastic Syndromes (MDS) CME, CPE Jamile M. Shammo, MD, FASCP, FACP | ||
Release Date: May 07, 2021 Expiration Date: May 07, 2022 | ||
Join Dr. Jamile Shammo as she explores challenges and advances in the management of hypomethylating agent (HMA) failure in myelodysplastic syndromes (MDS). Topics will include potential mechanisms of resistance, distinguishing between HMA failure and HMA-related cytopenia, current standard care following HMA failure, and notable clinical trials for treatment of MDS patients with HMA failure. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc. | ||
View Only, No Credit | ||
Updates in MDS: A Special Edition on Higher-risk Disease CME, CPE Mikkael S. Sekeres, MD, MS | ||
Release Date: April 21, 2021 Expiration Date: April 21, 2022 | ||
In this activity, Dr. Sekeres will discuss the current and future treatment landscape for higher-risk MDS. He will provide advice for distinguishing higher-risk MDS from lower-risk MDS, review appropriate treatment goals, and outline current treatment algorithms for higher-risk disease. He will also outline exciting advances in the treatment and management of higher-risk MDS, including a review of the data on the NEDD8 inhibitor pevonedistat, APR 246 targeting TP53-mutations and novel combinations. Provided by MediCom Worldwide, Inc.This activity is supported by an educational grant from Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited. | ||
View Only, No Credit | ||
Chronic Anemia in MDS: Focus on Newer Strategies for ESA-refractory or Relapsed Patients CME, CPE David Sallman, MD | ||
Release Date: April 05, 2021 Expiration Date: April 05, 2022 | ||
In this activity, Dr. Sallman will review conventional strategies and explore emerging concepts for managing MDS and chronic anemia in those who have relapsed after or are refractory to erythropoiesis stimulating agents (ESAs). Topics will include the phase 3 COMMAND trial comparing luspatercept versus ESAs as frontline treatment for patients with lower-risk MDS and anemia; the role of lenalidomide with ESAs for non-ring sideroblast MDS and/or del 5q-mutated MDS; the first-in-class telomerase inhibitor imetelstat; treatment targets within the pyroptosis/inflammasome activation pathway; and the data supporting novel hypomethylating agent doublets for frontline care of high-risk MDS, including azacitidine with magrolimab, azacitidine with pevonedistat, and azacitidine with sabatolimab. Provided by MediCom Worldwide, Inc.This activity is supported by educational grants from Bristol-Myers Squibb and Taiho Oncology, Inc. | ||
View Only, No Credit | ||
Practical Approaches to the Treatment in High- or Very High-Risk MDS Patients CME, CPE Richard A. Larson, MD | ||
Release Date: June 10, 2020 Expiration Date: June 10, 2021 | ||
The subset of patients with high-risk MDS are often older patients who may not be eligible for more intensive treatments. In this activity, Dr. Larson will review the IPSS and IPSS-R criteria used to define these patients. He will also review risk factors associated with high-risk MDS and the goals of therapy. Lastly, he discusses key genetic mutations that should be addressed, including emerging agents that are of potential interest in this group of patients. Provided by MediCom Worldwide, Inc. This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology. | ||
View Only, No Credit | ||